IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

JUN 1 2 2007



In re Applicant:

Michael FAINZILBER et al

Serial No.:

10/559,871

Filed:

May 2, 2006

For:

Neuronal Regeneration And Compound Administration

Methods

Examiner:

MARVICH, MARIA

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 *\$* \$\text{\$\}\$}}}}\text{\$\text{\$\text{\$\text{\$\text{\$\text{\$\text{\$\text{\$\exititt{\$\text{\$\text{\$\text{\$\text{\$\text{\$\text{\$\text{\$\text{\$\text{\$\text{\$\text{\$\text{\$\text{\$\text{\$\text{\$\text{\$\text{\$\

Group Art Unit: 1641

Attorney

Docket: 30750

INFORMATION DISCLOSURE STATEMENT

Sir:

Enclosed is a PTO Form 1449 which lists citations which may be material to the patentability and examination of the above identified application. Also enclosed are copies of the references cited. These are submitted in compliance with the duty of disclosure defined in 37 CFR 1.56. The Examiner is requested to make these citations of official record in this application.

This Information Disclosure Statement under 37 CFR 1.56 is not to be construed as a representation that a search has been made, that additional matter which is material to the examination of this application does not exist, or that any or more of these citations constitutes prior art.

Respectfully submitted,

late O. Hoyuka

Martin D. Moynihan

Registration No. 40,338

Dated: June 10, 2007

Approved for use through 06/30/2006. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

ion of information unless it contains a valid OMB control number. Under the Paperwork Reduction Act of 1995, no persons are requ

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known Application Number 10/559,871 May 2, 2006 Filing Date First Named Inventor Michael FAINZILBER et al Group Art Unit 1641 Examiner Name MARVICH, MARIA

(use as many sheets as necessary)		Examiner Name MARVICH, MARIA					
Sheet	1	Of 4	Attorney Docket Number	30750			
		OTHER PRIOR ART – NON PATI	ENT LITERATURE DOC	UMENTS			
Examiner Initials	Cite No.1		catalog, etc.) date, page(s), volun ountry where published.	ne-issue number(s),	T ²		
	1	Horgan et al. "Examining the Mechanism of Erk Nuclear Translocation Using Green					
		Fluorescent Protein", Experimental Cell Ro § 1, Fig.1.	esearch, 285: 208-220, 20	03. P.210, Col.1,			
	2	Swissprot "UniProtKB/Swiss-Prot Entry C	000629 and O06142".				
			http://ca.expasy.org/uniprot/O00629//Q06142, 6 P. & 8 P., 1997/1998.				
	3	Bridger et al. "Identification of An Interchromosomal Compartment by					
		Polymerization of Nuclear-Targeted Vimentin", Journal of Cell Science, 111: 1241-					
		1253, 1998. P.1242, Col.2, Last §, Fig.1.	,	,			
	4	Imbron et al. "Priming Events and Retrograde Injury Signals. A New Perspective on					
	'	the Cellular and Molecular Biology of Nerve Regeneration", Molecular					
		Neurobiology, 13: 61-79, 1996.	,	}			
	5		nance Growth, Survival, a	nd Excitability of			
		Ambron et al. "Intrinsic Injury Signals Enhance Growth, Survival, and Excitability of Aplysia Neurons", The Journal of Neuroscience, 16(23): 7469-7477, 1996.					
	6	Andersen et al. "Herpesvirus-Mediated Gene Delivery Into the Rat Brain: Specificity					
		and Efficiency of the Neuron-Specific Enolase Promoter", Cellular and Molecular					
		Neurobiology, 13(5): 503-515, 1993.	,				
	7	Blesch et al. "Nucleus Hears Axon's Pain".	Nature Medicine, 10(3):	236-237, 2004.			
	8	Bogerd et al. "Definition of A Consensus 7					
		Transport Signal", The Journal of Biologic					
	9	Boyne et al. "Role of Vimentin in Early St					
		Hippocampal Neurons", International Jour 739-748, 1996.					
	10	Clarke et al. "Intermediate Filaments: Vim R596-R598, 2002.	entin Moves in", Current	Biology, 12:			
	11	Colucci-Guyon et al. "Mice Lacking Vime Obvious Phenotype", Cell, 79: 679-694, 19		ace Without An			
	12	Döhner et al. "Function of Dynein and Dyn	nactin in Hernes Simplex	Virus Capsid			
	1.2	Transport", Molecular Biology of the Cell		- · F			
	13	Eckes et al. "Impaired Wound Healing in I		e Lacking	-		
		Vimentin", Journal of Cell Science, 113: 2					
	14	Ferrigno et al. "Regulated Nucleo/Cytopla	smic Exchange of HOG1	MAPK Requires			
		the Importin β Homologs NMD5 and XPC	01", The EMBO Journal, 1	7(19): 5606-			
		5614, 1998.	,				
	15	Geles et al. "Germline and Developmental	Roles of the Nuclear Tran	nsport Factor			
		Importin α3 in C. Elegans", Devlopment,					
	16	Gunawardena et al. "Cargo-Carrying Moto	or Vehicles on the Neuron	al Highway:			
		Transport Pathways and Neurodegenerativ					
		258-271, 2004.	•				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

considered. Include copy of this form with next communication to applicant.

1. Applicant's unique citation designation number (optional).

2. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 06/30/2006. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known Application Number 10/559,871 May 2, 2006 Filing Date First Named Inventor Michael FAINZILBER et al Group Art Unit 1641 MARVICH, MARIA Examiner Name

(use as many sheets as necessary)		Examiner Name MARVICH, MARIA				
Sheet	2 Of 4		Attorney Docket Number	30750		
		OTHER PRIOR ART – NON PATE	ENT LITERATURE DOC	UMENTS		
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTER item (book, magazine, journal, serial symposium, c publisher, city and/or co	catalog, etc.) date, page(s), volun ountry where published.	ne-issue number(s),	T ²	
	17	Hanz et al. "Axoplasmic Importins Enable Retrograde Injury Signaling in Lesioned Nerve", Neuron, 40: 1095-1104, 2003.				
	18	Ho et al. "Novel Features of Intermediate F Fluorescent Protein Chimeras", Journal of	Cell Science, 111: 1767-1	778, 1998.		
	19	Inagaki et al. "Spatial Patterns of Ca2+ Sig Signaling by Ca2+/Calmodulin-Dependent Biological Chemistry, 272(40): 25195-251	Protein Kinase II", The J 99, 1997.	ournal of		
	20	Jäkel et al. "Importins Fulfil A Dual Functi Cytoplasmic Chaperones for Exposed Basi 377-386, 2002.	ic Domains", The EMBO	Journal, 21(3):		
	21	Jans et al. "Nuclear Targeting Signal Reco Transport?", BioEssays, 22(6): 532-544, 20	000.			
	22	Kaspar et al. "Targeted Retrograde Gene D Molecular Therapy, 5(1): 50-56, 2002.				
	23	Kenney et al. "Peripheral Axotomy Induce Kinase-1 Activation and Activator Protein- Adult Rat Dorsal Root Ganglia In Vitro", 7 1328, 1998.	 1 Binding Activity by C 	Jun and JunD in		
	24	Köhler et al. "Evidence for Distinct Substruments in Nuclear Protein Import", Mole 7791, 1999.				
	25	Kumar et al. "Perturbing Nuclear Transpor Specific Cell Adhesion and Axon Guidanc 315-325, 2001.	rt in Drosophila Eye Imag e Defects", Developmenta	inal Discs Causes al Biology, 240:		
	26	Lam et al. "Nuclear Transport of Parathyro Dependent on Microtubules", Molecular E	indocrinology, 16(2): 390-	401, 2002.		
	27	Lariviere et al. "Functions of Intermediate Disease", Journal of Neurobiology, 58: 13	Filaments in Neuronal De 1-148, 2004.	evelopment and		
	28	Lowrie Jr. et al. "Properties of the Nonheli Role in Maintaining Intermediate Filament Biology, 132: 83-94, 2000.	t Network Structure", Jour	rnal of Structural		
	29	Mavlyutov et al. "Identification of RanBP2 Pathways With Restricted Neuronal and Science 640, 2002.	ubcellular Localization",	Γraffic, 3: 630-		
	30	Menet et al. "Axonal Plasticity and Function Mice Deficient in Both Glial Fibrillary Ac Natl. Acad. Sci. USA, 100(15): 8999-9004	idic Protein and Vimentin 4, 2003.	Genes", Proc.		
	31	Miller et al. "On Trk for Retrograde Signa				
	32	Paramio et al. "Beyond Structure: Do Inter Signalling?", BioEssays, 24(9): 836-844, 2		late Cell		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

'Applicant's unique citation designation number (optional).

'Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 06/30/2006. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

of information unless it contains a valid OMB control number. Under the Paperwork Reduction Act of 1995, no persons are require

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known Application Number 10/559,871 Filing Date May 2, 2006 First Named Inventor Michael FAINZILBER et al Group Art Unit 1641 MARVICH, MARIA **Examiner Name**

Sheet	3	Of 4	Attorney Docket Number	30750	-	
		OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.				
	33	Pardridge "Drug and Gene Targeting to the Brain With Molecular Trojan Horses", Nature Reviews: Drug Discovery, 1: 131-139, 2002.				
	34	Perlson et al. "Differential Proteomics Rev Transported Axoplasm After Nerve Injury' 510-520, 2004.	", Molecular & Cellular Pr	roteomics, 3(5):		
	35	Perlson et al. "From Snails to Sciatic Nerve: Retrograde Injury Signaling From Axon to Soma in Lesioned Neurons", Journal of Neurobiology, 58: 287-294, 2004.				
	36	Plunet et al. "Promoting Axonal Regeneration in the Central Nervous System by Enhancing the Cell Body Response to Axotomy", Journal of Neuroscience Research, 68: 1-6, 2002.				
	37	Rogers et al. "Truncation Mutagenesis of the Non-α-Helical Carboxyterminal Tail Domain of Vimentin Reveals Contributions to Cellular Localization But Not to Filament Assembly", European Journal of Cell Biology, 66: 136-150, 1995.				
	38	Salehi et al. "Traffic at the Intersection of I Neurodegeneration", Trends in Neuroscien	Neurotrophic Factor Signa			
	39	Schmied et al. "A Nuclear Localization Sig Transport System, Thereby Evading Uptak Journal of Neurobiology, 33: 151-160, 199	gnal Targets Proteins to the te Into Organelles in Aply			
	40	Smith et al. "Nuclear Localization Signal F Cytoskeleton", The Plant Cell, 10: 1791-17	Receptor Importin α Assoc 799, 1998.			
	41	Smith et al. "A Transcription-Dependent S Neurons for Distinct Modes of Axon Grow 646-658, 1997.	vth", The Journal of Neuro	oscience, 17(2):		
	42	Sung et al. "RISK-1: A Novel MAPK Hon Retrogradely Transported After Nerve Inju 2001.	iry", Journal of Neurobiol	ogy, 47: 67-79,		
	43	Vallee et al. "Dynein: An Ancient Motor P Transport", Journal of Neurobiology, 58: 1		le Modes of	_	
	44	Weis "Regulating Access to the Genome: In the Cell Cycle", Cell, 112: 441-451, 2003.	Nucleocytoplasmic Transp			
	45	Wellmann et al. "Retrograde Transport of Neurons", The Journal of Biological Chem	nistry, 276(15): 11821-118	329, 2001.		
	46	Yano et al. "Mechanisms of Neurotrophin Neurobiology, 58: 244-257, 2003.	Receptor Vesicular Trans	port", Journal of	:	
	47	Zhang et al. "Positive Injury Signals Induc Neurons", Journal of Neurobiology, 45: 84		rvival in Aplysia	-	

C:	Considered	
Signature	 Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

considered. Include copy of this form with next communication to applicant.

1. Applicant's unique citation designation number (optional).

2. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including the publication forms to the USPTO. Time will vary depending upon the individual case. Any comments on the amount osphoto process) an application. Commercially is governed by 35 0.722 and 57 of the first of the USPTO. The shift of the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

of information unless it contains a valid OMB control number. Under the Paperwork Reduction Act of 1995, no persons are re

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known Application Number 10/559,871 May 2, 2006 Filing Date Michael FAINZILBER et al First Named Inventor 1641 Group Art Unit

			Group Fire Office	1.0				
	(use a	s many sheets as necessary)	Examiner Name	MARVICH, MARI	A			
Sheet	4	Of 4	Attorney Docket Number	30750				
3	<u> </u>	OTHER PRIOR ART – NON PAT	ENT LITERATURE DO	CUMENTS				
Examiner	Cite	Include name of the author (in CAPITAL LETTE)	RS), title of the article (when ap	propriate), title of the				
nitials	No.1	item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s),						
		publisher, city and/or country where published. Zheng et al. "A Functional Role for Intra-Axonal Protein Synthesis During Axonal						
	48							
		Regeneration From Adult Sensory Neurons", The Journal of Neuroscience, 21(23): 9291-9303, 2001.						
	49	Perlson et al. "Vimentin Binding to Phosphorylated Erk Sterically Hinders						
		Enzymatic Dephosphorylation of the Kinase", Journal of Molecular Biology,						
		Published Online: DOI: 10.1016/j.jmb.2006.09.056, 2006.						
110	50	Hanz et al. "Retrograde Signaling in Injured Nerve - The Axon Reaction Revisited",						
		Journal of Neurochemistry, 99: 13-19, 2006.						
	51	Olofsdotter et al. "Importin mediated Nuclear Transport in Neurons", Current						
		Opinion in Neurobiology, 16: 329-335, 20						
	52		Helfand et al. "Internediate Filament Proteins Participate in Signal Transduction",					
		Trends in Cell Biology, 15(11): 568-570, 2005.						
	53	Perlson et al. "Vimentin-Dependent Spatial Translocation of An Activated MAP						
	"	Kinase in Injured Nerve", Neuron, 45: 715-726, 2005.						
	54	Thompson et al. "Synapse to Nucleus Signaling During Long-Term Synaptic						
	•	Plasticity: A Role for the Classical Active Nuclear Import Pathway", Neuron, 44:						
		997-1009, 2004.	,	, , , , , , , , , , , , , , , , , , ,				
	55	Harel et al. "Importin Beta: Conducting A	Much Larger Cellular Sy	mphony",				
		Molecular Cell, 16: 319-330, 2004.	2	• • •				
	56	Hanz et al. "Integration of Retrograde Ax	onal and Nuclear Transpo	rt Mechanisms in				
		Neurons: Implications for Therapeutics", The Neuroscientist, 10(5): 404-408, 2004.						
	<u> </u>							
	-							
	1	-						
								
	<u> </u>							
	-							
								
	-							
								
	-							
Signature			C	onsidered				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

1. Applicant's unique citation designation number (optional).

2. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.